Early study of AZD8205 for advanced solid tumors
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have an advanced or metastatic solid tumor that has already been treated with standard care, or your doctor feels a trial is best next
- Your cancer has measurable spots that can be tracked by scans
- You feel well enough for treatment (ECOG performance status 0 or 1) and are expected to live at least 12 weeks
- Your blood counts and organ function (bone marrow, liver, kidneys) meet lab safety levels
- You must have one of the specific eligible cancer types for a sub-study (like breast, ovarian, endometrial, biliary tract, or certain lung cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.